Last edition
News about "Bcl-2 Inhibitor Lisaftoclax "
Ascentage Pharma Gets NDA Approval for Bcl-2 Inhibitor Lisaftoclax
This NDA is based on results from a pivotal registrational Phase II study in China (APG2575CC201) that evaluated the efficacy and safety of lisaftoclax in patients with r/r CLL/SLL.
Bcl-2 Inhibitor Lisaftoclax | 18/11/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members